source
- ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancerSac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first…BioSpace · 19d ago↗ source
- Incyte reports strong early results for KRAS G12D inhibitor in pancreatic cancer, rivals RevMedIncyte presented phase 1 data at the European Society for Medical Oncology congress in Madrid, highlighting its KRAS G12D inhibitor INCB161734 combined with chemotherapy for pancreatic ductal adeno…